for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Palatin Technologies, Inc.

PTN

Latest Trade

0.43USD

Change

0.00(+0.09%)

Volume

495,470

Today's Range

0.42

 - 

0.43

52 Week Range

0.38

 - 

1.30

As of on the Nyse American LLC ∙ Minimum 15 minute delay

Latest Developments

Palatin Reports Fourth Quarter And Full Year Fiscal Year 2021 Financial Results

Sept 29 (Reuters) - Palatin Technologies Inc <PTN.A>::PALATIN REPORTS FOURTH QUARTER AND FULL YEAR FISCAL YEAR 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.PALATIN TECHNOLOGIES- PHASE 3 STUDY OF PL9643 IN PATIENTS WITH DRY EYE DISEASE EXPECTED TO START NEXT QUARTER WITH TOP-LINE RESULTS EXPECTED IN H2 2022.PALATIN - PHASE 2 STUDY OF PL8177 IN PATIENTS WITH ULCERATIVE COLITIS EXPECTED TO START NEXT QUARTER WITH TOP-LINE RESULTS EXPECTED IN H2 2022.PALATIN TECHNOLOGIES - $60.1 MILLION IN CASH AND CASH EQUIVALENTS AT JUNE 30, 2021 - PROJECTED CASH RUNWAY THROUGH CALENDAR 2022.PALATIN TECHNOLOGIES INC - QTRLY LOSS PER SHARE $0.06.

Palatin Announces Positive End-Of-Phase 2 Meeting With FDA On Pl9643 For The Treatment Of Dry Eye Disease

June 29 (Reuters) - Palatin Technologies Inc <PTN.A>::PALATIN ANNOUNCES POSITIVE END-OF-PHASE 2 MEETING WITH FDA ON PL9643 FOR THE TREATMENT OF DRY EYE DISEASE.PALATIN TECHNOLOGIES - CO, FDA REACH AGREEMENT ON PATH TO NDA SUBMISSION, INCLUDING TRIAL DESIGN, ENDPOINTS, INTERIM ASSESSMENT, PATIENT POPULATION.PALATIN TECHNOLOGIES INC - ON TRACK TO INITIATE PHASE 3 STUDY CALENDAR Q4 2021 WITH DATA EXPECTED CALENDAR 2H 2022.PALATIN TECHNOLOGIES INC - IF PHASE 3 PROGRAM PROGRESSES AS PLANNED, NDA SUBMISSION IS TARGETED FOR SECOND HALF OF CALENDAR YEAR 2023.

Palatin Reports Q3 Loss Per Share Of $0.02

May 17 (Reuters) - Palatin Technologies Inc <PTN.A>::Q3 LOSS PER SHARE $0.02.Q3 EARNINGS PER SHARE ESTIMATE $-0.03 -- REFINITIV IBES DATA.SAYS $68.6 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2021.

Palatin Technologies Reports Q2 Fiscal Year 2021 Financial Results And Recent Business Highlights

Feb 17 (Reuters) - Palatin Technologies Inc <PTN.A>::PALATIN TECHNOLOGIES, INC. REPORTS SECOND QUARTER FISCAL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q2 LOSS PER SHARE $0.04.Q2 EARNINGS PER SHARE ESTIMATE $-0.02 -- REFINITIV IBES DATA.Q2 SALES $944,000.Q2 REVENUE ESTIMATE $302,000 -- REFINITIV IBES DATA.

Palatin Technologies Announces Filing Of International Patent Application Claiming PL9643

Feb 10 (Reuters) - Palatin Technologies Inc <PTN.A>::PALATIN TECHNOLOGIES ANNOUNCES FILING OF INTERNATIONAL PATENT APPLICATION CLAIMING PL9643.PALATIN TECHNOLOGIES INC - PHASE 2/3 CLINICAL TRIAL CURRENTLY PLANNED FOR MID-2021.PALATIN TECHNOLOGIES INC - ANTICIPATE FILING PATENT APPLICATIONS IN U.S., EUROPE AND A NUMBER OF ADDITIONAL REGIONS AND COUNTRIES THROUGHOUT WORLD.

Palatin Technologies Announces Positive Results From Phase 2 Study Of Pl9643 In Patients With Dry Eye Disease

Dec 15 (Reuters) - Palatin Technologies Inc <PTN.A>::PALATIN TECHNOLOGIES ANNOUNCES POSITIVE RESULTS FROM ITS PHASE 2 STUDY OF PL9643 IN PATIENTS WITH DRY EYE DISEASE.PALATIN TECHNOLOGIES INC - PHASE 2/3 CLINICAL TRIAL CURRENTLY PLANNED FOR MID-2021.PALATIN TECHNOLOGIES INC - THERE WERE NO SAFETY SIGNALS IDENTIFIED AND PL9643 HAD EXCELLENT OCULAR TOLERABILITY IN TRIAL.PALATIN TECHNOLOGIES INC - STATISTICALLY SIGNIFICANT IMPROVEMENT IN MODERATE-TO-SEVERE PATIENTS FOR MULTIPLE SIGN AND SYMPTOM MEASURES IN STUDY.PALATIN TECHNOLOGIES INC - STATISTICAL SIGNIFICANCE FOR PRIMARY ENDPOINTS WAS NOT REACHED IN OVERALL ENROLLED POPULATION IN STUDY.

Palatin Technologies Inc Reports First Quarter Fiscal Year 2021 Results And Provides Business Update

Nov 17 (Reuters) - Palatin Technologies Inc <PTN.A>::PALATIN TECHNOLOGIES, INC. REPORTS FIRST QUARTER FISCAL YEAR 2021 RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.02.FROM JULY 25 TO SEPT 30 VYLEESI GROSS SALES $809,100 .PHASE 2 CLINICAL RESULTS OF PL9643 FOR TREATMENT OF DRY EYE DISEASE ON TRACK FOR DECEMBER 2020.ANTICIPATES FILING AN IND & COMMENCING CLINICAL TRIALS WITH PL8177 FOR NON-INFECTIOUS UVEITIS, , IN H2 OF CALENDAR YEAR 2021.PALATIN TECHNOLOGIES -CONTINUES ITS WORK RELATED TO TREATMENT OF PATIENTS WITH DIABETIC RETINOPATHY, WITH IND FILING TARGETED FOR MID-CALENDAR YEAR 2021.PALATIN TECHNOLOGIES- TO POTENTIALLY FILE AN IND WITH FDA, INITIATE A CLINICAL STUDY OF PL8177 FOR TREATMENT OF COVID-19 PATIENTS EARLY IN Q1 OF 2021.

Palatin Technologies Reports Q1 Loss Per Share $0.02

Nov 17 (Reuters) - Palatin Technologies Inc <PTN.A>::PALATIN TECHNOLOGIES, INC. REPORTS FIRST QUARTER FISCAL YEAR 2021 RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.02.Q1 SALES $809,100.PHASE 2 CLINICAL RESULTS OF PL9643 FOR TREATMENT OF DRY EYE DISEASE ON TRACK FOR DECEMBER 2020.ANTICIPATES FILING AN IND & COMMENCING CLINICAL TRIALS WITH PL8177 FOR NON-INFECTIOUS UVEITIS, , IN H2 OF CALENDAR YEAR 2021.PALATIN TECHNOLOGIES -CONTINUES ITS WORK RELATED TO TREATMENT OF PATIENTS WITH DIABETIC RETINOPATHY, WITH IND FILING TARGETED FOR MID-CALENDAR YEAR 2021.PALATIN TECHNOLOGIES- TO POTENTIALLY FILE AN IND WITH FDA, INITIATE A CLINICAL STUDY OF PL8177 FOR TREATMENT OF COVID-19 PATIENTS EARLY IN Q1 OF 2021.

Palatin Technologies Reports Q4 Loss Per Share Of $0.03

Sept 28 (Reuters) - Palatin Technologies Inc <PTN.A>::PALATIN TECHNOLOGIES, INC. ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2020 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE.Q4 LOSS PER SHARE $0.03.Q4 EARNINGS PER SHARE ESTIMATE $-0.02 -- REFINITIV IBES DATA.PALATIN TECHNOLOGIES - BELIEVES EXISTING CAPITAL RESOURCES WILL BE SUFFICIENT TO FUND CO'S PLANNED OPERATIONS THROUGH AT LEAST SEPT. 30, 2021.PALATIN TECHNOLOGIES - PHASE 2 STUDY DATA OF PL9643 FOR TREATMENT OF DRY EYE DISEASE EXPECTED IN FOURTH CALENDAR QUARTER OF 2020.

Palatin Technologies Announces Reinitiation Of Enrollment Of Phase 2 Study With Pl9643 For Treatment Of Dry Eye Disease

July 8 (Reuters) - Palatin Technologies Inc <PTN.A>::PALATIN TECHNOLOGIES, INC. ANNOUNCES REINITIATION OF ENROLLMENT OF PHASE 2 STUDY WITH PL9643 FOR THE TREATMENT OF DRY EYE DISEASE.PALATIN TECHNOLOGIES INC - DATA READOUT TARGETED FOR Q4 OF CALENDAR YEAR 2020.PALATIN TECHNOLOGIES - PATIENT ENROLLMENT FOR PL9643 PHASE 2 CLINICAL STUDY IS CURRENTLY EXPECTED TO BE COMPLETE WITHIN NEXT 30-45 DAYS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up